Greg Kunst, Aurion Biotech CEO
Aurion raises $120M in bid to scale cell therapy for form of blindness
To treat corneal endothelial dysfunction, a condition that causes the outer layer of the eye to swell and go hazy, doctors generally rely on cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
